Merck Acquired OncoEthix
Global healthcare leader Merck (NYSE:MRK) acquired OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Financial terms of the acquisition include an upfront payment of up to $110m to OncoEthix. Additional milestone payments of up to $265m are contingent upon certain clinical and regulatory events being achieved. Founded in 2009 and led by […]